Free Trial

VistaGen Therapeutics (VTGN) Competitors

VistaGen Therapeutics logo
$4.05 0.00 (0.00%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$4.11 +0.06 (+1.36%)
As of 10/17/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VTGN vs. FULC, INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, and AUTL

Should you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Fulcrum Therapeutics (FULC), Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry.

VistaGen Therapeutics vs. Its Competitors

VistaGen Therapeutics (NASDAQ:VTGN) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Fulcrum Therapeutics has a consensus price target of $9.60, suggesting a potential upside of 6.79%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Fulcrum Therapeutics is more favorable than VistaGen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VistaGen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Fulcrum Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

78.4% of VistaGen Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fulcrum Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VistaGen Therapeutics$490K253.58-$51.42M-$1.78-2.28
Fulcrum Therapeutics$80M6.08-$9.73M-$1.22-7.37

Fulcrum Therapeutics' return on equity of -31.05% beat VistaGen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VistaGen TherapeuticsN/A -74.06% -64.10%
Fulcrum Therapeutics N/A -31.05%-28.96%

In the previous week, Fulcrum Therapeutics had 6 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 1 mentions for VistaGen Therapeutics. Fulcrum Therapeutics' average media sentiment score of 0.31 beat VistaGen Therapeutics' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
VistaGen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fulcrum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

VistaGen Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the S&P 500.

Summary

Fulcrum Therapeutics beats VistaGen Therapeutics on 14 of the 16 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTGN vs. The Competition

MetricVistaGen TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$124.26M$3.40B$6.10B$10.49B
Dividend YieldN/A2.28%5.73%4.80%
P/E Ratio-2.2823.1685.3827.13
Price / Sales253.58269.13520.13179.96
Price / CashN/A47.1837.2361.22
Price / Book1.6610.4112.236.52
Net Income-$51.42M-$52.77M$3.33B$276.93M
7 Day Performance0.50%2.31%1.18%1.93%
1 Month Performance33.22%11.13%6.16%2.19%
1 Year Performance31.92%11.12%60.00%35.00%

VistaGen Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTGN
VistaGen Therapeutics
0.4898 of 5 stars
$4.05
flat
N/A+32.4%$124.26M$490K-2.2840News Coverage
FULC
Fulcrum Therapeutics
1.3999 of 5 stars
$8.75
-2.7%
$9.60
+9.7%
+153.2%$486.28M$80M-7.17100News Coverage
INBX
Inhibrx Biosciences
2.0332 of 5 stars
$34.38
+5.9%
N/A+130.4%$470.27M$200K-3.25166
ATXS
Astria Therapeutics
2.0855 of 5 stars
$8.47
+1.9%
$29.50
+248.3%
+1.9%$468.97MN/A-4.2130Trending News
Analyst Downgrade
CYRX
CryoPort
3.1705 of 5 stars
$9.40
+1.1%
$12.56
+33.6%
+41.9%$465.62M$228.38M7.071,186News Coverage
SLDB
Solid Biosciences
3.0047 of 5 stars
$6.01
+0.8%
$15.00
+149.6%
-7.0%$464.10M$8.09M-2.15100
ALMS
Alumis
3.4337 of 5 stars
$4.61
+3.8%
$20.17
+337.5%
-59.6%$462.05MN/A0.00N/APositive News
Gap Down
DRUG
Bright Minds Biosciences
3.2134 of 5 stars
$64.97
+2.7%
$81.00
+24.7%
+191.0%$445.81MN/A-69.86N/APositive News
LXEO
Lexeo Therapeutics
3.0458 of 5 stars
$8.20
-0.5%
$17.00
+107.3%
+5.3%$444.97M$650K-2.5258Trending News
Analyst Forecast
Insider Trade
Gap Up
RAPT
Rapt Therapeutics
3.159 of 5 stars
$26.35
-1.6%
$24.78
-6.0%
+117.0%$443.05M$1.53M-1.8680Analyst Revision
Gap Down
AUTL
Autolus Therapeutics
3.4134 of 5 stars
$1.65
-0.6%
$9.12
+452.7%
-65.5%$441.80M$10.12M-1.96330

Related Companies and Tools


This page (NASDAQ:VTGN) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners